Literature DB >> 7225285

The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.

S Dische, M I Saunders, P J Riley, J Hauck, M H Bennett, M R Stratford, A I Minchinton.   

Abstract

The concentration of desmethylmisonidazole (DESMISO) was determined in 60 biopsy samples taken from 13 human tumours and in cerebrospinal fluid (CSF) from 8 patients after oral administration. In comparison with misonidazole (MISO), peak concentrations in plasma were reached at earlier times and half-lives were shorter, so that the area under the curve of plasma concentration with time (AUC) was reduced by 45%; the AUC of CSF concentration with time was reduced by 67%. Between 1 and 2 h after administration of DESMISO, concentrations in tumours were generally 85-90% of those of MISO estimated approximately 4 h after it was given. The two drugs when tested in equimolar concentrations have been found in laboratory experiment to be equally potent as hypoxic cell radiosensitizers. Recognizing the lower mol. wt of DESMISO and the trend to higher concentrations in the more necrotic areas of the tumours studied equal doses by weight of the two drugs given orally may give equal radiosensitization of hypoxic cells in human tumours.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7225285      PMCID: PMC2010594          DOI: 10.1038/bjc.1981.54

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  Misonidazole-a drug for trial in radiotherapy and oncology.

Authors:  S Dische; M I Saunders; I R Flockhart; M E Lee; P Anderson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-06       Impact factor: 7.038

2.  Radiosensitizers of hypoxic cells in solid tumors.

Authors:  J F Fowler; G E Adams; J Denekamp
Journal:  Cancer Treat Rev       Date:  1976-12       Impact factor: 12.111

3.  Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole.

Authors:  J M Brown; P Workman
Journal:  Radiat Res       Date:  1980-04       Impact factor: 2.841

4.  Malignant melanoma arising at tattoo sites used for radiotherapy field marking.

Authors:  A H Bartal; Y Cohen; E Robinson
Journal:  Br J Radiol       Date:  1980-09       Impact factor: 3.039

5.  A drug for improved radiosensitization in radiotherapy.

Authors:  S Dische; J F Fowler; M I Saunders; M R Stratford; P Anderson; A I Minchinton; M E Lee
Journal:  Br J Cancer       Date:  1980-07       Impact factor: 7.640

6.  Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors:  S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

7.  Distribution of misonidazole in human tumours and normal tissues.

Authors:  D V Ash; M R Smith; R D Bugden
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640

8.  Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.

Authors:  R A White; P Workman
Journal:  Br J Cancer       Date:  1980-02       Impact factor: 7.640

  8 in total
  1 in total

1.  The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study.

Authors:  M I Saunders; S Dische; D Fermont; A Bishop; I Lenox-Smith; J G Allen; S L Malcolm
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.